Barclays Remains a Buy on UCB SA (0NZT)
Barclays analyst Charles Pitman CFA maintained a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €240.00.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Pitman CFA is a 4-star analyst with an average return of 9.2% and a 48.51% success rate. Pitman CFA covers the Healthcare sector, focusing on stocks such as UCB SA, Lonza Group Ltd, and arGEN X.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for UCB SA with a €211.00 average price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
36 minutes ago
- Business Insider
Capricor treatment of Becker muscular dystrophy granted orphan designation
The FDA granted orphan designation to a treatment of Becker muscular dystrophy being developed by Capricor, according to a post to the agency's website. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
an hour ago
- Business Insider
Stifel Nicolaus Remains a Buy on RegenXBio (RGNX)
In a report released today, Annabel Samimy from Stifel Nicolaus reiterated a Buy rating on RegenXBio (RGNX – Research Report), with a price target of $40.00. The company's shares opened today at $9.72. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Samimy is a 4-star analyst with an average return of 4.0% and a 42.89% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, RegenXBio, and Altimmune. Currently, the analyst consensus on RegenXBio is a Strong Buy with an average price target of $31.27, representing a 221.71% upside. In a report released on May 28, Leerink Partners also maintained a Buy rating on the stock with a $19.00 price target.
Business Insider
an hour ago
- Business Insider
Bank of America Securities Sticks to Its Buy Rating for RegenXBio (RGNX)
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $22.00. The company's shares opened today at $9.72. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Stranahan covers the Healthcare sector, focusing on stocks such as Novavax, RegenXBio, and Candel Therapeutics. According to TipRanks, Stranahan has an average return of -9.6% and a 39.81% success rate on recommended stocks. RegenXBio has an analyst consensus of Strong Buy, with a price target consensus of $31.27, a 221.71% upside from current levels. In a report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $40.00 price target. Based on RegenXBio's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $89.01 million and a net profit of $6.08 million. In comparison, last year the company earned a revenue of $15.62 million and had a GAAP net loss of $63.33 million
